Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer

Lung cancer is the leading cause of death worldwide. Despite emergence highly effective targeted therapies, up to 30% advanced stage non-small cell lung (NSCLC) patients do not undergo tissue molecular testing because scarce availability. Liquid biopsy, on other hand, offers these a valuable opportunity receive best treatment options in timely manner. Indeed, besides being much faster and less invasive than conventional tissue-based analysis, it can also yield specific information about genetic make-up evolution patients’ tumors. However, several issues, including lack standardized protocols for sample collection, processing, interpretation, still need be addressed before liquid biopsy fully incorporated into routine oncology practice. Here, we reviewed most important challenges hindering implementation practice, as well great advantages this approach NSCLC patients.